Evidence map›Paper›PMID 28458888›Full record

ArticleEndocrinology, diabetes & metabolism case reports2017

Diabetic ketoacidosis: a challenging diabetes phenotype.

Cliona Small, Aoife M Egan, El Muntasir Elhadi, Michael W O'Reilly, Aine Cunningham, Francis M Finucane

Open access · goldAbstract read
In one paragraph

Article in Endocrinology, diabetes & metabolism case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Risperidone-induced type 2 diabetes presenting with diabetic ketoacidosis.Endocrinology, diabetes & metabolism case reports · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Cliona SmallHRB Clinical Research Facility, Galway University Hospitals, National University of Ireland, GalwayIreland.
Aoife M EganHRB Clinical Research Facility, Galway University Hospitals, National University of Ireland, GalwayIreland.
El Muntasir ElhadiHRB Clinical Research Facility, Galway University Hospitals, National University of Ireland, GalwayIreland.
Michael W O'ReillyHRB Clinical Research Facility, Galway University Hospitals, National University of Ireland, GalwayIreland.
Aine CunninghamHRB Clinical Research Facility, Galway University Hospitals, National University of Ireland, GalwayIreland.
Francis M FinucaneHRB Clinical Research Facility, Galway University Hospitals, National University of Ireland, GalwayIreland.
Ollscoil na Gaillimhe – University of Galway · IEUniversity Hospital Galway · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryWe describe three patients presenting with diabetic ketoacidosis secondary to ketosis prone type 2, rather than type 1 diabetes. All patients were treated according to a standard DKA protocol, but were subsequently able to come off insulin therapy while maintaining good glycaemic control. Ketosis-prone type 2 diabetes (KPD) presenting with DKA has not been described previously in Irish patients. The absence of islet autoimmunity and evidence of endogenous beta cell function after resolution of DKA are well-established markers of KPD, but are not readily available in the acute setting. Although not emphasised in any current guidelines, we have found that a strong family history of type 2 diabetes and the presence of cutaneous markers of insulin resistance are strongly suggestive of KPD. These could be emphasised in future clinical practice guidelines. LEARNING POINTS: Even in white patients, DKA is not synonymous with type 1 diabetes and autoimmune beta cell failure. KPD needs to be considered in all patients presenting with DKA, even though it will not influence their initial treatment.Aside from markers of endogenous beta cell function and islet autoimmunity, which in any case are unlikely to be immediately available to clinicians, consideration of family history of type 2 diabetes and cutaneous markers of insulin resistance might help to identify those with KPD and are more readily apparent in the acute setting, though not emphasised in guidelines.Consideration of KPD should never alter the management of the acute severe metabolic derangement of DKA, and phasing out of insulin therapy requires frequent attendance and meticulous and cautious surveillance by a team of experienced diabetes care providers.

Identifiers

PMID28458888
PMCPMC5404460
OpenAlexW2593339514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.